Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Biotech
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Health
STAT+

Can the popular vaccine FluMist make a comeback in the U.S.?

  • Helen Branswell

By Helen Branswell Feb. 20, 2018

Reprints
FluMist
TIM SLOAN/AFP/Getty Images

This week could be pivotal for the fate of the popular influenza vaccine known as FluMist and its manufacturer MedImmune, a division of AstraZeneca.

On Wednesday, the Advisory Committee on Immunization Practices will hear a pitch the company hopes will persuade it to restore its recommendation for use of FluMist, the only non-injectable flu vaccine licensed in the United States.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Helen Branswell

Helen Branswell

Senior Writer, Infectious Diseases

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Post News.

Tags

Stanford scientist who broke genome sequencing record on what…
Stanford scientist who broke genome sequencing record on what faster diagnoses mean for patients
Will there be any emergency doctors to see you…
Will there be any emergency doctors to see you in the future?
Pharmalittle: U.K. regulator to streamline clinical trial approvals; NIH…
Pharmalittle: U.K. regulator to streamline clinical trial approvals; NIH won’t seize patents to cut price of…
NIH rejects bid to cut a cancer drug’s price…
NIH rejects bid to cut a cancer drug’s price by sidestepping patents
89bio treatment reduces liver scarring in patients with NASH,…
89bio treatment reduces liver scarring in patients with NASH, meeting study goals
Carrying the torch of his slain brother, a Chicago…
Carrying the torch of his slain brother, a Chicago ER doctor struggles against the violence around…

Recommended Stories